Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate

Biomaterials

Volumn 31, Issue 19, 2010, Pages 5258-5265

  Park, Kitae ^a   Lee, Min Young ^a   Kim, Ki Su ^a   Hahn, Sei Kwang ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

Gene silencing; Hyaluronic acid; Polyethyleneimine; SiRNA; Target delivery

Indexed keywords

BISACRYLAMIDE; CELLULAR UPTAKE; CYSTAMINE; CYTOSOLS; GENE SILENCING; HYALURONIC ACIDS; IN-VITRO; LOW MOLECULAR WEIGHT; MICROSCOPIC ANALYSIS; MRNA EXPRESSION LEVEL; POLYETHYLENEIMINE; RECEPTOR-MEDIATED ENDOCYTOSIS; SERUM STABILITY; SMALL INTERFERING RNA (SIRNA); TARGET DELIVERY; TUMOR GROWTH; TUMOR TREATMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR;

BODY FLUIDS; GENE EXPRESSION; GENETIC ENGINEERING; ORGANIC ACIDS; ORGANIC POLYMERS; TARGETS; TUMORS;

RNA;

HYALURONIC ACID; POLYETHYLENEIMINE; SMALL INTERFERING RNA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; COMPLEX FORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOSOL; DEGRADATION KINETICS; DOWN REGULATION; DRUG CYTOTOXICITY; ENDOCYTOSIS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; TUMOR;

ANIMALS; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; GENE THERAPY; HYALURONIC ACID; MELANOMA; MICE; MICE, INBRED BALB C; POLYETHYLENEIMINE; RNA, SMALL INTERFERING; TRANSFECTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952289449     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.03.018     Document Type: Article

References (39)

1. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004, 32:e149.
2. Qin X.F., An D.S., Chen I.S., Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A 2003, 100:183-188.
3. Aagaard L., Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007, 59:75-86.
4. White P.J. Barriers to successful delivery of short interfering RNA after systemic administration. Clin Exp Pharmacol Physiol 2008, 35:1371-1376.
5. Mao S., Sun W., Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev 2009.
6. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005, 12:461-466.
7. Patil M.L., Zhang M., Betigeri S., Taratula O., He H., Minko T. Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug Chem 2008, 19:1396-1403.
8. Leng Q., Scaria P., Zhu J., Ambulos N., Campbell P., Mixson A.J. Highly branched HK peptides are effective carriers of siRNA. J Gene Med 2005, 7:977-986.
9. Endoh T., Ohtsuki T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev 2009, 61:704-709.
10. Sioud M., Sorensen D.R. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 2003, 312:1220-1225.
11. Dalby B., Cates S., Harris A., Ohki E.C., Tilkins M.L., Price P.J., et al. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods 2004, 33:95-103.
12. Akinc A., Zumbuehl A., Goldberg M., Leshchiner E.S., Busini V., Hossain N., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008, 26:561-569.
13. Sato Y., Murase K., Kato J., Kobune M., Sato T., Kawano Y., et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 2008, 26:431-442.
14. Li S.D., Huang L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm 2006, 3:579-588.
15. Gary D.J., Puri N., Won Y.Y. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release 2007, 121:64-73.
16. Zhang S., Zhao B., Jiang H., Wang B., Ma B. Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release 2007, 123:1-10.
17. Maruyama K., Iwasaki F., Takizawa T., Yanagie H., Niidome T., Yamada E., et al. Novel receptor-mediated gene delivery system comprising plasmid/protamine/sugar-containing polyanion ternary complex. Biomaterials 2004, 25:3267-3273.
18. Koyama Y., Ito T., Matsumoto H., Tanioka A., Okuda T., Yamaura N., et al. Novel poly(ethylene glycol) derivatives with carboxylic acid pendant groups: synthesis and their protection and enhancing effect on non-viral gene transfection systems. J Biomater Sci Polym Ed 2003, 14:515-531.
19. Plank C., Mechtler K., Szoka F.C., Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther 1996, 7:1437-1446.
20. Takei Y., Kadomatsu K., Yuzawa Y., Matsuo S., Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004, 64:3365-3370.
21. Pirollo K.F., Zon G., Rait A., Zhou Q., Yu W., Hogrefe R., et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 2006, 17:117-124.
22. Kumar P., Ban H.S., Kim S.S., Wu H., Pearson T., Greiner D.L., et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008, 134:577-586.
23. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005, 23:1002-1007.
24. Filleur S., Courtin A., Ait-Si-Ali S., Guglielmi J., Merle C., Harel-Bellan A., et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 2003, 63:3919-3922.
25. Choi Y.S., Lee J.Y., Suh J.S., Kwon Y.M., Lee S.J., Chung J.K., et al. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 2010, 31:2429-2443.
26. Kim S.H., Jeong J.H., Kim T.I., Kim S.W., Bull D.A. VEGF siRNA delivery system using arginine-grafted bioreducible poly(disulfide amine). Mol Pharm 2009, 6:718-726.
27. Jiang G., Park K., Kim J., Kim K.S., Hahn S.K. Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis. Mol Pharm 2009, 6:727-737.
28. Jiang G., Park K., Kim J., Kim K.S., Oh E.J., Kang H., et al. Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA. Biopolymers 2008, 89:635-642.
29. Forrest M.L., Koerber J.T., Pack D.W. A degradable polyethylenimine derivative with low toxicity for highly efficient gene delivery. Bioconjug Chem 2003, 14:934-940.
30. Fischer D., Bieber T., Li Y., Elsasser H.P., Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999, 16:1273-1279.
31. Breunig M., Lungwitz U., Liebl R., Goepferich A. Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc Natl Acad Sci U S A 2007, 104:14454-14459.
32. Gosselin M.A., Guo W., Lee R.J. Efficient gene transfer using reversibly cross-linked low molecular weight polyethylenimine. Bioconjug Chem 2001, 12:989-994.
33. Christensen L.V., Chang C.W., Kim W.J., Kim S.W., Zhong Z., Lin C., et al. Reducible poly(amido ethylenimine)s designed for triggered intracellular gene delivery. Bioconjug Chem 2006, 17:1233-1240.
34. Hoon Jeong J., Christensen L.V., Yockman J.W., Zhong Z., Engbersen J.F., Jong Kim W., et al. Reducible poly(amido ethylenimine) directed to enhance RNA interference. Biomaterials 2007, 28:1912-1917.
35. Asayama S., Nogawa M., Takei Y., Akaike T., Maruyama A. Synthesis of novel polyampholyte comb-type copolymers consisting of a poly(l-lysine) backbone and hyaluronic acid side chains for a DNA carrier. Bioconjug Chem 1998, 9:476-481.
36. Alexis F., Lo S.L., Wang S. Covalent attachment of low molecular weight poly(ethylene imine) improves tat peptide mediated gene delivery. Adv Mater 2006, 18:2174-2178.
37. Culty M., Nguyen H.A., Underhill C.B. The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol 1992, 116:1055-1062.
38. Prevo R., Banerji S., Ferguson D.J., Clasper S., Jackson D.G. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem 2001, 276:19420-19430.
39. Alaniz L., Rizzo M., Malvicini M., Jaunarena J., Avella D., Atorrasagasti C., et al. Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response. Cancer Lett 2009, 278:9-16.